↓ Skip to main content

Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma

Overview of attention for article published in BMC Cancer, May 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma
Published in
BMC Cancer, May 2016
DOI 10.1186/s12885-016-2344-8
Pubmed ID
Authors

Mari Poukka, Andrey Bykachev, Hanna Siiskonen, Kristiina Tyynelä-Korhonen, Päivi Auvinen, Sanna Pasonen-Seppänen, Reijo Sironen

Abstract

Hyaluronan is a large extracellular matrix molecule involved in several biological processes such as proliferation, migration and invasion. In many cancers, hyaluronan synthesis is altered, which implicates disease progression and metastatic potential. We have previously shown that synthesis of hyaluronan and expression of its synthases 1-2 (HAS1-2) decrease in cutaneous melanoma, compared to benign melanocytic lesions. In the present study, we compared immunohistological staining results of HAS1 and HAS2 with clinical and histopathological parameters to investigate whether HAS1 or HAS2 has prognostic value in cutaneous melanoma. The specimens consisted of 129 tissue samples including superficial (Breslow ≤ 1 mm) and deep (Breslow > 4 mm) melanomas and lymph node metastases. The differences in immunostainings were analysed with non-parametric Mann-Whitney U test. Associations between immunohistological staining results and clinical parameters were determined with the χ(2) test. Survival between patient groups was compared by the Kaplan-Meier method using log rank test and Cox's regression model was used for multivariate analyses. The expression of HAS1 and HAS2 was decreased in deep melanomas and metastases compared to superficial melanomas. Decreased immunostaining of HAS2 in melanoma cells was significantly associated with several known unfavourable histopathologic prognostic markers like increased mitotic count, absence of tumor infiltrating lymphocytes and the nodular subtype. Furthermore, reduced HAS1 and HAS2 immunostaining in the melanoma cells was associated with increased recurrence of melanoma (p = 0.041 and p = 0.006, respectively) and shortened disease- specific survival (p = 0.013 and p = 0.001, respectively). This study indicates that reduced expression of HAS1 and HAS2 is associated with melanoma progression and suggests that HAS1 and HAS2 have a prognostic significance in cutaneous melanoma.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 23%
Researcher 4 18%
Student > Ph. D. Student 4 18%
Student > Bachelor 2 9%
Professor 1 5%
Other 2 9%
Unknown 4 18%
Readers by discipline Count As %
Medicine and Dentistry 6 27%
Biochemistry, Genetics and Molecular Biology 4 18%
Agricultural and Biological Sciences 3 14%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Nursing and Health Professions 1 5%
Other 2 9%
Unknown 5 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2017.
All research outputs
#12,453,219
of 18,940,883 outputs
Outputs from BMC Cancer
#3,285
of 6,862 outputs
Outputs of similar age
#157,031
of 274,833 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 18,940,883 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,862 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,833 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them